newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC